The full name

email@vos.com

Top Biotech News (19 Feb 2025)

Top Biotech News (19 Feb 2025)

Biotech IPO Challenges and Strategies

Summary:

CEOs of Septerna, Upstream Bio and Actuate share insights on IPO preparation, timing, team building, and market navigation in challenging biotech investment climate of 2024-2025.

Roche-Licensed Biotech Launches with $94M Investment

Summary:

Newleos Therapeutics debuts with four clinical-stage brain drugs from Roche, focusing on anxiety and substance use disorders. Goldman Sachs leads funding with Novo Holdings support.

Immunology & Inflammation Market Growth Accelerates

Summary:

Rising investment in I&I sector drives novel drug development and M&A activity, targeting diseases like IBD and atopic dermatitis with projected market value of $257B by 2032.

Biogen’s Latest Rare Disease Investment

Summary:

Biogen partners with Stoke Therapeutics on Dravet syndrome drug zorevunersen in $165M upfront deal, with potential for $385M more, sharing global development rights.

New HIF-2a Drug Shows Promise in Kidney Cancer

Summary:

Arcus Biosciences’ casdatifan demonstrates 33% response rate and 9.7-month progression-free survival in Phase I/Ib trial, potentially rivaling Merck’s Welireg.

Subscribe
to the latest updates in the newsletter

Related Solutions

Organoid Service

  • Disease Modeling
  • Oncology
  • Organoid
Organoid Service

Research service

  • Cosmetics
  • OECD TG
  • Zebrafish
Research service

Technical service

  • Bioinfomatics
  • Holotomography
  • Molecular biology
  • Spatial Biology
Technical service

Next Articles

Connect with Us

By submitting your details, you confirm that you have reviewed and agree with the Lambda Biologics Privacy Policy.